CRISPR hires William Blair analyst as new finance chief; Tiny EU biotech raises $20M+
Less than 18 months after hiring Brendan Smith as CFO, CRISPR Therapeutics is bringing in another exec to take his place.
The Swiss-American gene editing biotech put out word Monday that it is hiring Raju Prasad as the company’s newest finance chief, effective Tuesday. Prasad joins from investment bank William Blair, where he was a senior research analyst covering gene editing and gene and cell therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.